TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03733405

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Postpartum Visit at 6 Weeks
Description: The patient will be scheduled for a routine postpartum visit at the standard time interval. Each postpartum visit will consist of the standard interview and physical examination. The purpose of this visit is for routine postpartum care. If she has a medical complication during delivery, she may be recommended to schedule an additional earlier visit.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Postpartum Visit at 6 Weeks
Description: The patient will be scheduled for a routine postpartum visit at the standard time interval. Each postpartum visit will consist of the standard interview and physical examination. The purpose of this visit is for routine postpartum care. If she has a medical complication during delivery, she may be recommended to schedule an additional earlier visit.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Postpartum Visit at 2 Weeks
Description: The patient will be scheduled for an earlier postpartum visit in addition to the standard time interval. Each postpartum visit will consist of the standard interview and physical examination. The purpose of this visit is for routine postpartum care. If she has a medical complication during delivery, she may be recommended to schedule an additional earlier visit.
Study: NCT00404365

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: counseling intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: counseling intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: counseling intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: counseling intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: screening questionnaire administration

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: screening questionnaire administration

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: screening questionnaire administration

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: screening questionnaire administration

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: study of socioeconomic and demographic variables

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: study of socioeconomic and demographic variables

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: study of socioeconomic and demographic variables

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: study of socioeconomic and demographic variables

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: psychosocial assessment and care

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: psychosocial assessment and care

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: psychosocial assessment and care

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: psychosocial assessment and care
Study: NCT01656889

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HP-802-247
Description: HP802-247 (fibrinogen solution \& thrombin solution containing living, irradiated, growth arrested keratinocytes and fibroblasts) 260 µL (130 µL, one spray, of each solution) containing 0.5 x 106 cells per mL every 14 days.
Study: NCT04360525

Intervention type: OTHER
Intervention: Reasons
Description: Causes of sigmoid volvulus

Intervention type: OTHER
Intervention: Reasons
Description: Causes of sigmoid volvulus
Study: NCT04311606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sub-tenon injection of saline followed by a sub-tenon injection of aflibercept
Description: The study will randomly assign a total of eight subjects into this treatment arm to receive a sub-tenon injection of saline followed by injection of 4 mg aflibercept (total volume 1.1 ml) in the worse eye. Injections will be given three times: on day 1, day 14 and day 28. Subjects will be followed until day 90.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sub-tenon injection of hyaluronidase (HA) followed by a sub-tenon injection of aflibercept
Description: The study will randomly assign a total of eight subjects into this treatment arm to receive a sub-tenon injection of hyaluronidase (HA) followed by injection of 4 mg aflibercept (total volume 1.1 ml) in the worse eye. Injections will be given three times: on day 1, day 14 and day 28. Subjects will be followed until day 90.
Study: NCT03645395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-3724
Description: Experimental treatment with MT-3724 in combination with LEN therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-3724
Description: Experimental treatment with MT-3724 in combination with LEN therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-3724
Description: Experimental treatment with MT-3724 in combination with LEN therapy.
Study: NCT04311606

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sub-tenon injection of hyaluronidase (HA) alone
Description: The study will randomly assign a total of eight subjects into this treatment arm to receive a sub-tenon injection of hyaluronidase (HA) injection alone (total volume 1.1 ml) in the worse eye. Injections will be given three times: on day 1, day 14 and day 28. Subjects will be followed until day 90.
Study: NCT03797521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SXC-2023
Description: SXC-2023 oral capsules
Study: NCT03797521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SXC-2023
Description: SXC-2023 oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SXC-2023
Description: SXC-2023 oral capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo oral capsules
Study: NCT03084666

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zimmer ATS tourniquet system
Description: The tourniquet is the same kind that is used in orthopedic surgeries to limit blood loss in arm or leg surgery. It can be inflated to a set pressure for a set amount of time.
Study: NCT01656889

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: (fibrinogen solution \& thrombin solution without cells)
Study: NCT01499082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HOE901-U300 (new formulation of insulin glargine)
Description: HOE901-U300 (new insulin glargine 300 units per milliliter \[U/mL\]) subcutaneous (SC) injection once daily (evening) for 12 months on top of mealtime insulin analogue. Dose titration seeking fasting plasma glucose 4.4-5.6 millimole per liter (mmol/L) (80 - 100 milligram per deciliter \[mg/dL\]). After 6 months participants were proposed to participate to the administration substudy and to receive either HOE901-U300 once daily at intervals of 24 +/- 3 hours (adaptable dosing intervals) or to continue once daily injections of HOE901-U300 every 24 hours (fixed dosing intervals) up to Month 9.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lantus (insulin glargine)
Description: Lantus (HOE901-U100, insulin glargine 100 U/mL) SC injection once daily (evening) for 12 months on top of mealtime insulin analogue. Dose titration seeking fasting plasma glucose 4.4-5.6 mmol/L (80 - 100 mg/dL).
Study: NCT03442712

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Auricular acupressure plus smartphone App
Description: Semen Vaccaria laccaria will be kept in place by a piece of adhesive patch. Seeds will be applied on one ear only, and seed plasters will be changed every 3 days to 4 days to the opposite ear, that is, we will meet the subjects twice per week. Subjects will be requested to apply pressure on the acupoints thrice per day, preferably within 30 min before eating, pressing for 20 times using a constant rhythm to each point. Coaching on how to self-administer AA on the acupoints will be given to the subjects, and a return demonstration from the subjects will be required to ensure the skills are performed properly. The subjects will install the smartphone App specifically designed for this study. The App will send out regular AA reminders to the subjects. In addition, the subjects will be asked to input the number of bowel open and compliance with AA performance per day into the App. The total treatment period will be 8 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Auricular acupressure
Description: The participants will receive AA treatment and are required to perform daily self-administered seeds pressing, but no smartphone App will be provided, but a booklet containing relevant information will be provided to the subjects.
Study: NCT02089256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: Graded glucose infusion test (GGIT)will be performed on baseline. 1 week later treatment with liraglutide 0.6mg/day (injected between 21.00-23.00) will be initiated.~GGIT will be repeated 12 hours after first injection and after 21 days on-treatment (12 hours after last injection).
Study: NCT04389450

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PLX-PAD
Description: PLX-PAD, allogeneic ex vivo expanded placental mesenchymal-like adherent stromal cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PLX-PAD
Description: PLX-PAD, allogeneic ex vivo expanded placental mesenchymal-like adherent stromal cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PLX-PAD
Description: PLX-PAD, allogeneic ex vivo expanded placental mesenchymal-like adherent stromal cells

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo solution for injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo solution for injection
Study: NCT02525965

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Wide resection margin >1cm
Description: Surgical removal of lesions choosing the method of wide resection margin \>1cm

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Narrow resection margin <1cm
Description: Surgical removal of lesions choosing the method of wide resection margin \<1cm
Study: NCT02522936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biotene oral spray
Description: Biotene oral spray will be provided to participants.
Study: NCT02254226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol Diskus low

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol Diskus high

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol MDI low

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol MDI high
Study: NCT00633464

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ixabepilone
Description: injection, intravenous (IV), until unacceptable toxicity or progression or 15 months after the Last Subject First Visit (LSFV), whichever comes first.~Ixabepilone 40 mg/m\^2 was administered as a 3-hour IV continuous infusion on Day 1 in a 21-day cycle provided the participant met the re-treatment criteria.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ixabepilone + cetuximab
Description: Ixabepilone: injection, IV, until unacceptable toxicity or progression or 15 months after the LSFV, whichever comes first.~Ixabepilone 40 mg/m\^2 was administered as a 3-hour IV continuous infusion on Day 1 in a 21-day cycle provided the participant meets the re-treatment criteria.~Cetuximab: injection, IV, until unacceptable toxicity or progression or 15 months after the LSFV, whichever comes first.~Cetuximab 400 mg/m\^2 was administered as a 2-hour IV loading dose via in-line filtration with an infusion pump, gravity drip, or a syringe pump on Day 1 of first cycle then 250 mg/m\^2 1-hour IV once a week, i.e. on Days 1, 8, and 15 of each cycle provided the participant meets the re-treatment criteria.
Study: NCT02478060

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Birch-SPIRE

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Birch-SPIRE
Study: NCT03030222

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin 10 mg Tab
Description: Empagliflozin 10 mg Tab

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Empagliflozin matching placebo
Study: NCT01563536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-267
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-267
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-450
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-450
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-333
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-333
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Tablet
Study: NCT01356355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herbmed plus
Description: one capsule of herbmed plus orally twice a day with meals till the ureteral stent is in situ.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One capsule twice a day daily till ureteral stent in situ

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tolterodine
Description: One capsule twice a day daily till ureteral stent in situ
Study: NCT01825681

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Affect
Description: Six-session skill-building program designed to raise levels of positive emotion when skills are practiced over the duration of the program.
Study: NCT02510430

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Re-Patterning Sitting Time Group
Description: This is a behavioral intervention to help women interrupt long bouts of sitting time by incorporating standing breaks into their lifestyle.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reducing Sitting Time Group
Description: This is a behavioral intervention to help women reduce their overall accumulated sitting time by 2 hours per day.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: This intervention consists solely of follow-up contact to control for attention effects and reduce attrition.
Study: NCT00753792

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylprednisolone
Description: methylprednisolone 1.000 mg/day intravenous administration during three days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: methylprednisolone 1.250 mg/day orally administered during three days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo of methylprednisolone administered intravenously (Arm 2) or orally (Arm 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo of methylprednisolone administered intravenously (Arm 2) or orally (Arm 1)
Study: NCT02674893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide

Intervention type: OTHER
Group type: OTHER
Intervention: Observation alone

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Observation alone
Study: NCT03580889

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atropine
Description: Comparison between atropine, glycopyrrolate and Normal Saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glycopyrrolate
Description: Comparison between glycopyrrolate, atropine and Normal saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline Flush, 0.9% Injectable Solution
Description: Comparison between Normal saline, atropine and glycopyrrolate
Study: NCT00844025

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pharmacist intervention
Description: Medication review, medication reconciliation, and pharmacotherapy recommendation.
Study: NCT00696410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc Acetate
Description: Zinc acetate 50 mg po TID for 10 months. Dose will be titrated to achieve ceruloplasmin levels \~10-12.
Study: NCT03249051

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Indirect Calorimetry
Description: Energy need is being determined using indirect Calorimetry
Study: NCT02478060

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Birch-SPIRE

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Birch-SPIRE

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Birch-SPIRE

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT03661437

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Actigraph
Description: Wear Actiwatch

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Actigraph
Description: Wear Actiwatch

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Systematic Light Exposure
Description: Undergo BWL treatment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Systematic Light Exposure
Description: Receive DWL treatment
Study: NCT02809183

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral suspension

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRC101
Description: oral suspension
Study: NCT03315975

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated influenza vaccine
Description: One dose of quadrivalent inactivated influenza vaccine
Study: NCT04188977

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Practice
Description: OTP Directors are able to ask their state health officials permission to use interim methadone treatment. The state officials are in turn able to ask officials from the Center of Substance Abuse Treatment for permission to provide interim methadone treatment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Implementation Facilitation
Description: Implementation Facilitation (IF) will consist of educational outreach to OTP staff, identification of local champions, training, performance feedback, and learning collaborative for OTP staff and state health department officials.
Study: NCT04058353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ELX/TEZ/IVA
Description: FDC tablet for oral administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IVA
Description: Mono-tablet for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVA
Description: Mono-tablet for oral administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TEZ/IVA
Description: Fixed-dose combination (FDC) tablet for oral administration.
Study: NCT03530592

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Seated Ankle Robot Training
Description: This intervention employs the use of an adaptive ankle robot control system over a 6-week intervention period.
Study: NCT02076724

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biological mesh
Study: NCT02434380

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Euro D
Description: Vitamin D3 Euro D 10,000 IU (1 tablet) plus Euro D Placebo (1 tablet) weekly, alternating with Euro D Placebo (2 tablets) weekly, starting at the second trimester and continued until delivery.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Euro D
Description: Vitamin D3 Euro D 10,000 IU (2 tablets, equivalent to 20,000 IU) weekly, starting at the second trimester and continued until delivery.
Study: NCT02226913

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2% lidocaine with 1:80,000 epinephrine
Description: 2% lidocaine with 1:80,000 epinephrine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% lidocaine with 1:80,000 epinephrine
Description: 2% lidocaine with 1:80,000 epinephrine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium bicarbonate
Description: 8.4% sodium bicarbonate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: sterile distilled water (Samen Pharmaceutical Co, Iran)
Study: NCT02658864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lafutidine
Description: comparison of different doses, sex and medication conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lafutidine
Description: comparison of different doses, sex and medication conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lafutidine
Description: comparison of different doses, sex and medication conditions
Study: NCT02118129

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: an educational video

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: wait listed